New app functions empower patients, caregivers and health care professionals to easily find and access Karmanos' large ...
On June 22, 2026, the U.S. Department of Health and Human Services (HHS) “Operation TrialBlazer”, a coordinated, department-wide initiative to ...
Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that ...
SILVIA-Powered SASI Benchmark Published by TrialSite News Identifies Disclosure Risk as Greater Systemic Challenge Than ...
QAIAx Microcities Clinical Trial provided an new patent filing update regarding the development of an open-source military-grade artificial general intelligence (AGI) platform named the QAIAx Cool ...
UCSF just launched one of the first trials to test whether attacking two proteins simultaneously can slow or stop Alzheimer's ...
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...